Vis enkel innførsel

dc.contributor.authorMagalhães, Eduardo Jorge Muniz
dc.contributor.authorSarin, Luciana Maria
dc.contributor.authorDel Sant, Lorena Catarina
dc.contributor.authorLucchese, Ana Cecília
dc.contributor.authorNakahira, Carolina
dc.contributor.authorTuena, Marco Aurélio
dc.contributor.authorPuertas, Camila Brito
dc.contributor.authorRodovalho Fava, Victor Augusto
dc.contributor.authorDelfino, Rodrigo Simonini
dc.contributor.authorSurjan, Juliana
dc.contributor.authorSteglich, Matheus Souza
dc.contributor.authorBarbosa, Matheus Ghossain
dc.contributor.authorAbdo, Guilherme
dc.contributor.authorDel Porto, José Alberto
dc.contributor.authorNemeroff, Charles B.
dc.contributor.authorCogo-Moreira, Hugo
dc.contributor.authorLacerda, Acioly Luiz Tavares
dc.contributor.authorMello, Andrea Feijo
dc.identifier.citationFrontiers in Psychiatry. 2021, 12, Artikkel 608499.en_US
dc.description.abstractBackground: A history of child sexual abuse (CSA) is related to higher suicide rates and poor treatment outcomes in depressed adult patients. Twenty years after the first study investigating the effects of ketamine/esketamine on depression and suicide, there is a lack of data on the CSA effects on this emerging treatment. Here, we assess the impact of CSA on adjunctive subcutaneous (SC) esketamine for treatment-resistant depression (TRD). Methods: A directed acyclic graphic (DAG) was designed to identify clinical confounders between CSA and esketamine predictors of response. The confounders were applied in a statistical model to predict depression symptom trajectory in a sample of 67 TRD outpatients. Results: The patient sample had a relatively high prevalence rate of CSA (35.82%). Positive family history of first-degree relatives with alcohol use disorder and sex were clinical mediators of the effects of esketamine in a CSA adult population. Overall, the presence of at least one CSA event was unrelated to esketamine symptom reduction. Conclusions: Unlike responses to conventional antidepressants and psychotherapy, CSA does not appear to predict poor response to esketamine.en_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.subjectchild sex abuseen_US
dc.subjecttreatment-resistant depressionen_US
dc.subjectdirected acyclic graphen_US
dc.titleA Clinical Rationale for Assessing the Impact of Childhood Sexual Abuse on Adjunctive Subcutaneous Esketamine for Treatment-Resistant Depressionen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.rights.holder© 2021 Magalhães, Sarin, Del Sant, Lucchese, Nakahira, Tuena, Puertas, Rodovalho Fava, Delfino, Surjan, Steglich, Barbosa, Abdo, Del Porto, Nemeroff, Cogo-Moreira, Lacerda and Mello.en_US
dc.subject.nsiVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Psykiatri, barnepsykiatri: 757en_US
dc.source.journalFrontiers in Psychiatryen_US

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal